NCNA NuCana plc
Financings ·
NuCana's cash rose to £24.3 million after two 2025 raises, but its 2025 net loss was £29.4 million and net cash used in operating activities was £7,467 thousand. The melanoma data for NUC-7738 come from an expansion study the release does not size.
The company says Nasdaq closed its listing matter and that its cash lasts into 2029. The release gives no cash balance or burn figure and does not say what steps restored compliance.
The combined price of $0.6454 per ADS is set below the $1.10 last sale price on May 5, 2025. Warrant terms and a zero exercise price option on the Series B warrants could issue far more ADSs than the 2,452,935 sold.
The offering is a best-efforts deal placed by Laidlaw & Company (UK) Ltd. Warrant terms with a zero exercise price option and reset provisions could push the number of ADSs issued far above the 16,049,383 offered.
Our latest story on this, dated May 7, 2025: "NuCana plc prices best-efforts offering of 2,452,935 ADSs with warrants". The story links the filing or release it is based on. Read the story.
NuCana plc trades under the ticker NCNA on NASDAQ.
NuCana plc is listed on NASDAQ.
The SEC Central Index Key (CIK) for NuCana plc is 1709626. Its filings are on SEC EDGAR.
20,809,854,947 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-19.
Our directory records NuCana plc under United Kingdom.
Our directory classifies NuCana plc as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for NuCana plc is US67022C3043.
aibio.space lists NuCana plc among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as X0.
Our latest story on NuCana, dated Mar 19, 2026: "NuCana says £24.3 million in cash should fund operations into 2029". NuCana's cash rose to £24.3 million after two 2025 raises, but its 2025 net loss was £29.4 million and net cash used in operating activities was £7,467 thousand. The melanoma data for NUC-7738 come from an expansion study the release does not size. Source.
From our story of Mar 19, 2026: The company expects that cash to fund operations into 2029. Source.
Our latest listing story, dated Sep 5, 2025: "NuCana says Nasdaq confirmed compliance and closed its listing matter". The company says Nasdaq closed its listing matter and that its cash lasts into 2029. The release gives no cash balance or burn figure and does not say what steps restored compliance. Source.
SEC records list NuCana plc's filer category as: Non-accelerated filer.
SEC records list its business address as 3 LOCHSIDE WAY, EDINBURGH, United Kingdom, EH12 9DT.
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Filed a registration statement for a share offering. SEC Form F-1. Source
Reported a financing. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio